CAR-NK cells: A promising cellular immunotherapy for cancer

Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid gro...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	EBioMedicine Ročník 59; s. 102975
Hlavní autori:	Xie, Guozhu, Dong, Han, Liang, Yong, Ham, James Dongjoo, Rizwan, Romee, Chen, Jianzhu
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.09.2020 Elsevier
Predmet:	Advanced Basic Science Cancer Chimeric antigen receptor Immunotherapy Internal Medicine NK cells Review TAM TCR CRS IgG GVHD ADCP SB iPSCs BaEV-gp Immunotherapy KIRs ADCC AML APCs NK cells VEGF Tregs GMP TME PBMCs PB NK BMP4 CAR-Ms TIRs MDSCs NCRs PB Chimeric antigen receptor CAR CAR-T ITAM TCR-T scFv UCB TIL LAK SCF SBRT CAR-NK HPCs NK Cancer baboon envelop glycoprotein T cell receptor hematopoietic progenitor cells antigen-presenting cells stereotactic body radiotherapy natural cytotoxicity receptors antibody-dependent cellular phagocytosis CAR-engineered T CAR-engineered NK regulatory T cells Natural killer tumour microenvironment induced pluripotent stem cells graft-versus-host disease good manufacturing practice sleeping beauty tumour-associated macrophages single-chain variable fragment terminal inverted repeats macrophages with CARs acute myeloid leukaemia umbilical cord blood peripheral blood mononuclear cells immunoglobulin G stem cell factor T regs antibody-dependent cell-mediated cytotoxicity PBMCs-derived NK cytokine release syndrome immunoreceptor tyrosine-based activation motif lymphokine-activated killer myeloid-derived suppressor cells killer cell Ig-like receptors vascular endothelial growth factor PiggyBac TCR-engineered T bone morphogenetic protein 4 tumour-infiltrating lymphocyte
ISSN:	2352-3964, 2352-3964
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	2352-3964 2352-3964
DOI:	10.1016/j.ebiom.2020.102975